Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 3, 2013, Pages 232-234

  Solfanelli, Andrea ^a   Curto, Martina ^a   Dimitri Valente, Giorgia ^a   Kotzalidis, Georgios D ^a   Gasperoni, Carlotta ^a   Sani, Gabriele ^a   Manfredi, Giovanni ^a   Rapinesi, Chiara ^a   Comparelli, Anna ^a   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BETAMETHASONE; BILIRUBIN GLUCURONIDE; CHLORPHENIRAMINE; CREATINE KINASE; ETANERCEPT; FOLIC ACID; LACTATE DEHYDROGENASE; METHOTREXATE; NORDAZEPAM; OLANZAPINE; PROMAZINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUDITORY HALLUCINATION; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DELUSION; DRUG DOSE INCREASE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MALE; MYSTICISM; OUTPATIENT; PSYCHIATRIC DEPARTMENT; RASH; RESTLESSNESS; SACROILIITIS; SCHIZOPHRENIFORM DISORDER; SELF ESTEEM; SLEEP DISORDER; SPEECH DISORDER; TREATMENT DURATION; TRUNK; VISUAL HALLUCINATION;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIPSYCHOTIC AGENTS; ARTHRITIS, JUVENILE; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; EXANTHEMA; HUMANS; MALE; PSYCHOTIC DISORDERS;

EID: 84876698272     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0121     Document Type: Letter

References (21)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. , Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Benito-León J, Mitchell AJ: Guillain-Barré-like syndrome associated with olanzapine hypersensitivity reaction. Clin Neuropharmacol 28: 150-151, 2005.
3. Chang HY, Ridky TW, Kimball AB, Hughes E, Oro AE: Eruptive xanthomas associated with olanzapine use. Arch Dermatol 139: 1045-1048, 2003.
4. Christen S, Gueissaz F, Anex R, Zullino DF: Acute generalized exanthematous pustulosis induced by olanzapine. Acta Medica (Hradec Králové) 49: 75-76, 2006.
5. Chue P, Chue J: A review of olanzapine pamoate. Expert Opin Pharmacother 13: 1661-1670, 2012.
6. Detke HC, Zhao F, Witte MM: Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: An insight from effect size comparison with historical oral data. BMC Psychiatry 12: 51, 2012.
7. Duggal MK, Singh A, Arunab H, Lolis JD, Guzik HJ: Olanzapineinduced vasculitis. Am J Geriatr Pharmacother 3: 21-24, 2005.
8. Espada G: Juvenile idiopathic arthritis. Part 1: Diagnosis, pathogenesis and clinical manifestations [in Spanish]. Arch Argent Pediatr 107: 441-448, 2009.
9. Frampton JE: Olanzapine long-acting injection: A review of its use in the treatment of schizophrenia. Drugs 70: 2289-2313, 2010.
10. Huang JL: New advances in juvenile idiopathic arthritis. Chang Gung Med J 35: 1-14, 2012.
11. Jhirwal OP, Parsad D, Basu D: Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol 43: 778-779, 2004.
12. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: A 24 week, randomized, double-blind trial of maintenance treatment in patient with schizophrenia. Am J Psychiatry 167: 181-189, 2010.
13. Lowney AC, McAleer MA, Bourke J: Occupational allergic contact dermatitis to olanzapine. Contact Dermatitis 62: 123-124, 2010.
14. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245, 1981.
15. Papaioannides D, Sinapidis D, Korantzopoulos P, Charalabopoulos K: A case of cutaneous vasculitis associated with olanzapine. Int J Low Extrem Wounds 5: 116-117, 2006.
16. Perry R, Wolberg J, Dicrescento S: Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. Am J Health Syst Pharm 69: 40-43, 2012.
17. Prevost P, Bédry R, Lacoste D, Ezzedine K, Haramburu F, Milpied B: Hypersensitivity syndrome with olanzapine confirmed by patch tests. Eur J Dermatol 22: 126-127, 2011.
18. Rashid J, Wang R, Ramer SL: Atypical antipsychotics and seborrheic dermatitis: Three case reports. Pharmacopsychiatry 40: 103-106, 2007.
19. Raz A, Bergman R, Eilam O, Yungerman T, Hayek T: A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 321: 156-158, 2001.
20. Reeves RR, Mack JE: Allergic reaction to depot risperidone but not to oral risperidone. J Clin Psychiatry 66: 949, 2005.
21. Sinnott BP, Mazzone T: Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation. Endocr Pract 12: 183-187, 2006.